A Study of the Early Disturbances in Vascular Hemostasis in Experimentally Induced Metabolic Syndrome

The unique characteristics of the early changes in vascular haemostasis during the development of metabolic syndrome are still unclear. This study aimed to examine the development of vascular dysfunction in experimentally induced metabolic syndrome. The study used 61 male Wistar rats aged 2.5-3 months. Thirty-two rats were given ad libitum access to 10% fructose dilution for drinking, while the remaining 29 control group rats were not given the fructose dilution. The study period was 8 weeks. We used biochemical, haematological, and statistical methods for investigation. The experimental rats received fructose, and we observed a deteriorating trend in their plasma lipid composition within 2 weeks. At the end of 4 weeks, it had further deteriorated, and it progressively worsened until the end of the experimental period. At the end of 2 weeks, there was significant reduction in the plasma antioxidant activity and rise in the levels of plasma lipid peroxidation products in the experimental rats. This effect persisted throughout the experimental period. At the end of 4 weeks, we observed imbalances in the metabolites; the plasma levels of arachidonic acid peaked by the 8th week; in addition, thromboxane B 2 levels rose by 37.3% and 6-keto-prostaglandin F 1 α levels reduced by 21.8%. This was accompanied by an increase in endothelin-1 and decrease in the total nitric oxide metabolites by 20.2% in the experimental rats. At the end of 2 weeks, there was a reduction in the anticoagulant and fibrinolytic activities of the vessels of the experimental group rats; this effect increased with time. By 4 weeks, the vascular regulation of platelet aggregation in response to collagen, adenosine diphosphate and ristomicin had weakened in the experimental rats. Under experimental conditions of fructose ingestion, there was evident progressive weakening of antiaggregatory, anticoagulative, and fibrinolytic abilities of the vascular endothelium due to the inhibition of the production of prostacyclin, nitric oxide, antithrombin III, and tissue activator plasminogen in the vessels with a simultaneous increase in the body mass of the rats and the development of biochemical abnormalities that were characteristic of metabolic syndrome.

[1]  S. Zavalishina.  Restoration of Physiological Activity of Platelets in New-Born Calves With Iron Deficiency , 2017 .

[2]  S. Zavalishina,et al.  Diagnostical Appreciation of Physiological Reaction of intravascular Thrombocytes’ Activity of two-Years-old Mice to Regular Physical Loads , 2017 .

[3]  N. Kutafina.  Platelet Parameters of Holstein Newborn Calves , 2017 .

[4]  S. Zavalishina,et al.  Aggregative Activity of Basic Regular Blood Elements and Vascular Disaggregating Control over It in Calves of Milk-vegetable Nutrition , 2017 .

[5]  Makurina On,et al.  Platelet-Activity Dependence on the Age of Rats with Experimental Dyslipidemia , 2016 .

[6]  I. Medvedev,et al.  Transcriptional Activity of Chromosome Nucleolar Organizing Regions in Population of Kursk Region , 2009, Bulletin of Experimental Biology and Medicine.

[7]  I. Medvedev,et al.  Relationship between the Chromosome Nucleoli-Forming Regions and Somatometric Parameters in Humans , 2009, Bulletin of Experimental Biology and Medicine.

[8]  Carla Ribeiro,et al.  Metabolic syndrome signs in Wistar rats submitted to different high-fructose ingestion protocols , 2008, British Journal of Nutrition.

[9]  Takahiko Nakagawa,et al.  Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. , 2007, The American journal of clinical nutrition.

[10]  I. Medvedev.  VASCULAR-PLATELET INTERACTION IN PREGNANT COWS , 2017 .

[11]  I. Medvedev,et al.  [Platelet Activity in Patients With Third Degree Arterial Hypertension and Metabolic Syndrome]. , 2016, Kardiologiia.

[12]  I. Medvedev.  [Dynamics of violations of intravascular platelet activity in rats during the formation of metabolic syndrome using fructose models]. , 2016, Voprosy pitaniia.

[13]  Артериальная гипертония,et al.  Fluvastatin effects on blood cell aggregation in patients with arterial hypertension and dyslipidemia , 2015 .

[14]  I. Medvedev,et al.  Platelet aggregation in clinically healthy persons of the second coming-of-age living in the Kursk oblast , 2015, Advances in Gerontology.

[15]  I. Medvedev,et al.  [Pathogenetic aspects of arterial hypertension in metabolic syndrome]. , 2011, Klinicheskaia meditsina.

[16]  I. Medvedev,et al.  [Primary hemostasis activity in patients with arterial hypertension and impaired glucose tolerance treated with trandolapril]. , 2011, Klinicheskaia meditsina.

[17]  I. Medvedev,et al.  [Pathogenetic aspects of hypertension in case of metabolic syndrome]. , 2010, Voenno-meditsinskii zhurnal.

[18]  I. Medvedev,et al.  [Effect of irbesartan of the function of hemocoagulative component of hemostasis in patients with arterial hypertension during metabolic syndrome]. , 2010, Klinicheskaia meditsina.

[19]  Medvedev In,et al.  Effect of lovastatin on adhesive and aggregation function of platelets in patients with arterial hypertension and dislipidemia , 2010 .

[20]  I. Medvedev,et al.  Activity of Platelet Hemostasis in Children with Spinal Deformities , 2010, Bulletin of Experimental Biology and Medicine.

[21]  Simonenko Vb,et al.  Aggregation function of platelets in persons with arterial hypertension and abdominal obesity , 2008 .

[22]  I. Medvedev,et al.  [Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome]. , 2008, Klinicheskaia meditsina.

[23]  I. Medvedev,et al.  [Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome]. , 2008, Klinicheskaia meditsina.

[24]  I. Medvedev.  [Correction of primary hemostasis in patients suffering from arterial hypertension with metabolic syndrome]. , 2007, Klinicheskaia meditsina.

[25]  I. Medvedev,et al.  [Comparative evaluation of the influence of sulfhydryl and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from atrerial hypertension with metabolic syndrome]. , 2007, Klinicheskaia meditsina.

[26]  I. Medvedev,et al.  [The antiaggregation activity of the vascular wall in patients suffering from arterial hypertension with metabolic syndrome]. , 2007, Klinicheskaia meditsina.

[27]  I. Medvedev,et al.  [The influence of hypocaloric diet on thrombocyte rheology in patients with metabolic syndrome]. , 2006, Klinicheskaia meditsina.

[28]  I. Medvedev,et al.  [Correction of thrombocyte hemostasis and biological age reduction in metabolic syndrome]. , 2005, Klinicheskaia meditsina.

[29]  I. Medvedev,et al.  [Comparative assessment of effects of qadropril and enalapril on intravascular activity of platelets in hypertensive patients with metabolic syndrome.]. , 2004, Kardiologiia.

[30]  I. Medvedev,et al.  [Effects of lisinopril on platelet aggregation in patients with arterial hypertension with metabolic syndrome]. , 2004, Kardiologiia.